Meridian Wealth Advisors LLC Buys Shares of 25,000 Inhibrx, Inc. (NASDAQ:INBX)

Meridian Wealth Advisors LLC purchased a new stake in Inhibrx, Inc. (NASDAQ:INBX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 25,000 shares of the company's stock, valued at approximately $385,000. Meridian Wealth Advisors LLC owned approximately 0.17% of Inhibrx at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. HighTower Advisors LLC bought a new position in shares of Inhibrx during the fourth quarter valued at about $12,039,000. Bank of New York Mellon Corp purchased a new stake in Inhibrx in the 4th quarter valued at about $792,000. Charles Schwab Investment Management Inc. bought a new position in shares of Inhibrx during the 4th quarter worth approximately $503,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management purchased a new position in shares of Inhibrx in the 4th quarter worth approximately $348,000. Finally, Corient Private Wealth LLC bought a new position in shares of Inhibrx in the fourth quarter valued at approximately $316,000. Institutional investors own 82.46% of the company's stock.

Inhibrx Trading Up 0.6 %

Shares of NASDAQ INBX traded up $0.08 during mid-day trading on Thursday, reaching $14.32. 46,745 shares of the company's stock were exchanged, compared to its average volume of 210,952. The firm has a 50-day moving average price of $13.35 and a two-hundred day moving average price of $14.61. Inhibrx, Inc. has a 52 week low of $10.80 and a 52 week high of $35.42.

Inhibrx (NASDAQ:INBX - Get Free Report) last posted its quarterly earnings data on Monday, March 17th. The company reported ($3.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.88) by ($0.21). The company had revenue of $0.10 million for the quarter. Equities research analysts predict that Inhibrx, Inc. will post 104.88 EPS for the current year.

Remove Ads

Analyst Upgrades and Downgrades

Separately, JMP Securities reiterated a "market perform" rating on shares of Inhibrx in a report on Wednesday, January 22nd.

About Inhibrx

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.